Current Edition


Aeromics Initiates Phase 1 Clinical Trial Of CNS Edema Inhibitor AER-271 In Healthy Human Volunteers

Aeromics, Inc. (“Aeromics” or “the Company”), a privately-held, clinical-stage pharmaceutical company focused on controlling cerebral edema for people affected by disabling and life-threatening severe ischemic …

Continue Reading →

Aminex Therapeutics Initiates First Clinical Trial of Novel Immunotherapy AMXT 1501 + DFMO in Cancer Patients

Polyamine depletion therapy represents a unique cancer immunotherapy approach Aminex Therapeutics, Inc., a clinical-stage drug development company focused on advancing a novel cancer immunotherapy, today …

Continue Reading →